The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12246089 B1

Date of Patent:

Mar. 11, 2025

Filed:

Apr. 01, 2021

Method for treatment of a viral-mediated infectious disease

Applicant:

Virothera Pharmaceuticals Llc, Wynantskill, NY (US);

Inventor:

Shaker A. Mousa, Wynantskill, NY (US);

Assignee:

VIROTHERA PHARMACEUTICALS LLC, Wynantskill, NY (US);

Attorney:

Schmeiser, Olsen & Watts, LLP

Primary Examiner:

Mark V Stevens

Int. Cl.

CPC ...

A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 9/48 (2006.01); A61K 9/50 (2006.01); A61K 9/51 (2006.01); A61K 31/167 (2006.01); A61K 31/4706 (2006.01); A61K 31/4965 (2006.01); A61K 31/573 (2006.01); A61K 31/727 (2006.01); A61K 33/30 (2006.01); A61K 47/02 (2006.01); A61K 47/06 (2006.01); A61K 47/32 (2006.01);

U.S. Cl.

CPC ...

A61K 9/0078 (2013.01); A61K 9/0073 (2013.01); A61K 9/008 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/4866 (2013.01); A61K 9/5015 (2013.01); A61K 9/5123 (2013.01); A61K 9/5138 (2013.01); A61K 31/167 (2013.01); A61K 31/4706 (2013.01); A61K 31/4965 (2013.01); A61K 31/573 (2013.01); A61K 31/727 (2013.01); A61K 33/30 (2013.01); A61K 47/02 (2013.01); A61K 47/06 (2013.01); A61K 47/32 (2013.01);

Abstract

A method for prevention or treatment of a viral-mediated infectious disease in a mammal. The mammal may be a human being. A therapeutic dose of a composition is administered, via an inhalation delivery apparatus, to the mammal. The composition includes microparticles and/or nanoparticles. The microparticles and/or nanoparticles include a first pharmaceutically active agent and a second pharmaceutically active agent. The first pharmaceutically active agent includes unfractionated heparin (UFH), Low Molecular Weight Heparin (LMWH), sulfated non-anticoagulant heparin (S-NACH) or combinations thereof. The second pharmaceutically active agent includes 10-30 mg of hydroxychloroquine in a form of hydroxychloroquine sulfate, 10-30 mg of favipiravir, or a combination thereof. The viral-mediated infectious disease is caused by one or more viruses in the mammal.

Find Patent Forward Citations